
Jonathan Gardner
Senior Reporter | @ByJonGardner673 articles by Jonathan Gardner
-
FDA advisers back agency plan to simplify COVID-19 vaccination
Jan. 26, 2023 -
Lilly to boost diabetes drug production with $450M factory investment
Jan. 24, 2023 -
BeiGene wins expanded approval for leukemia drug, intensifying battle with AbbVie, AstraZeneca
Jan. 20, 2023 -
Roche says Tecentriq immunotherapy reduces risk of liver cancer recurrence
Jan. 19, 2023 -
Novo Nordisk diabetes pill wins FDA approval for first-line use
Jan. 13, 2023 -
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
Jan. 11, 2023 -
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
Jan. 10, 2023 -
Arrowhead reports positive data from liver drug, but company’s shares slide
Jan. 9, 2023 -
5 questions facing the pharma industry in 2023
Jan. 9, 2023 -
5 FDA decisions to watch in the first quarter
Jan. 9, 2023 -
Pfizer pares back early-stage research in rare disease, cancer
Jan. 6, 2023 -
Novocure shares soar on positive lung cancer data
Jan. 5, 2023 -
Pharma companies boost drug prices to start year, but hikes lag inflation
Jan. 3, 2023 -
FDA approval of Biogen Alzheimer’s drug was ‘rife with irregularities,’ congressional report says
Dec. 30, 2022 -
FDA sets decision date for Alvotech’s Humira biosimilar
Dec. 22, 2022 -
Government spending bill would tighten FDA oversight of accelerated drug approvals
Dec. 20, 2022 -
Roche, Biogen sign royalty deal for late-stage lymphoma drug
Dec. 19, 2022 -
Lilly lays out ambitious plans for 2023
Dec. 14, 2022 -
Moderna vaccine succeeds in early-stage skin cancer study with Merck’s Keytruda
Dec. 13, 2022 -
Roche’s hemophilia gene therapy holds steady with longer-term data
Dec. 12, 2022 -
MEI, Kyowa stop lymphoma drug trials after FDA meeting
Dec. 6, 2022 -
Roche study failure gives Alzheimer’s researchers new clues in drug quest
Dec. 1, 2022 -
Roche pulls Tecentriq in bladder cancer, completing sweep of ‘dangling’ accelerated approvals
Nov. 29, 2022 -
FDA grants speedy review to Sarepta’s Duchenne gene therapy
Nov. 28, 2022 -
Teva taps Sandoz veteran to take over CEO post from Schultz
Nov. 21, 2022